Abstract
Background: Patients with 46,XY differences of sex development (DSD) due to 17β-hydroxysteroid dehydrogenase type 3 (17βHSD3) deficiency are generally assigned female at birth. With known future virilizing puberty, orchiectomy is often discussed with patients and their families. Decision-making and factors to consider around orchiectomy are complex and challenging. We report two patients who presented at different ages to highlight the considerations and complexities surrounding gonad management, including the likelihood of gonadal malignancy, the possibility of fertility and options for preservation, and the current knowledge of gender identity outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
